MeSH term
Frequency | Condition_Probility | Carrier Proteins/*genetics | 4 | 0.0 |
Gene Frequency | 8 | 0.0 |
Genotype | 24 | 0.0 |
Humans | 48 | 0.0 |
Polymerase Chain Reaction | 8 | 0.0 |
Polymorphism, Genetic | 8 | 0.0 |
Receptor, Serotonin, 5-HT2A | 22 | 57.0 |
Receptors, Adrenergic, beta-2/*genetics | 2 | 8.0 |
Receptors, Serotonin/*genetics | 20 | 28.0 |
Polymorphism, Restriction Fragment Length | 3 | 0.0 |
Polymorphism, Single Nucleotide/*genetics | 3 | 1.0 |
Adolescent | 4 | 0.0 |
Adult | 18 | 0.0 |
Aged | 3 | 0.0 |
Aged, 80 and over | 2 | 0.0 |
*Alleles | 2 | 0.0 |
DNA/genetics | 2 | 0.0 |
Female | 25 | 0.0 |
Male | 25 | 0.0 |
Membrane Glycoproteins/*genetics | 2 | 0.0 |
*Membrane Transport Proteins | 6 | 1.0 |
Middle Aged | 9 | 0.0 |
*Nerve Tissue Proteins | 6 | 1.0 |
Promoter Regions (Genetics)/genetics | 3 | 0.0 |
Receptors, Dopamine D2/genetics | 2 | 4.0 |
Receptors, Serotonin/genetics | 6 | 31.0 |
Research Support, Non-U.S. Gov't | 29 | 0.0 |
Alleles | 11 | 0.0 |
Family Health | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 9 | 0.0 |
Cytochrome P-450 Enzyme System/genetics | 2 | 1.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
Linkage (Genetics) | 6 | 0.0 |
Comparative Study | 11 | 0.0 |
Cysteine/genetics | 2 | 1.0 |
Linkage Disequilibrium | 6 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 2 | 0.0 |
Threonine/genetics | 2 | 2.0 |
Age of Onset | 2 | 0.0 |
Genetic Heterogeneity | 2 | 0.0 |
*Polymorphism, Single Nucleotide | 4 | 0.0 |
Risk | 2 | 0.0 |
Chi-Square Distribution | 3 | 0.0 |
Polymorphism, Genetic/*genetics | 9 | 0.0 |
English Abstract | 2 | 0.0 |
Membrane Glycoproteins/genetics | 6 | 3.0 |
Schizophrenia/*genetics | 5 | 2.0 |
Animals | 7 | 0.0 |
Molecular Sequence Data | 4 | 0.0 |
Antipsychotic Agents/adverse effects | 2 | 16.0 |
Dyskinesia, Drug-Induced/*genetics | 2 | 18.0 |
Genetic Markers | 6 | 0.0 |
*Polymorphism, Genetic | 7 | 0.0 |
Schizophrenia/drug therapy/*genetics | 2 | 12.0 |
Child | 2 | 0.0 |
Haplotypes | 7 | 0.0 |
Pedigree | 3 | 0.0 |
Reference Values | 2 | 0.0 |
Homozygote | 3 | 0.0 |
Bipolar Disorder/*genetics | 3 | 2.0 |
Europe | 2 | 0.0 |
Biological Markers | 2 | 0.0 |
Membrane Transport Proteins/genetics | 2 | 6.0 |
Monoamine Oxidase/genetics | 3 | 13.0 |
Nerve Tissue Proteins/genetics | 2 | 0.0 |
Serotonin/*metabolism | 2 | 4.0 |
Tryptophan Hydroxylase/genetics | 5 | 35.0 |
Carrier Proteins/genetics | 3 | 0.0 |
Jews/*genetics | 2 | 1.0 |
Polymorphism, Genetic/genetics | 2 | 0.0 |
Receptor, Serotonin, 5-HT2C | 3 | 15.0 |
Logistic Models | 2 | 0.0 |
Variation (Genetics)/*genetics | 2 | 0.0 |
Depressive Disorder/*genetics | 2 | 10.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
Chromosomes, Human, Pair 13/genetics | 2 | 3.0 |
Odds Ratio | 2 | 0.0 |
Analysis of Variance | 2 | 0.0 |
Schizophrenia/*drug therapy/*genetics | 2 | 15.0 |
Clozapine/*pharmacology/therapeutic use | 2 | 40.0 |
Receptors, Serotonin/*genetics/metabolism | 2 | 66.0 |
Case-Control Studies | 2 | 0.0 |
Receptor, Serotonin, 5-HT2A/*genetics | 4 | 50.0 |
Base Sequence | 4 | 0.0 |
DNA Primers | 3 | 0.0 |
Schizophrenia/drug therapy/genetics | 2 | 50.0 |
Gene Expression/*genetics | 2 | 1.0 |
Blood Proteins/genetics | 2 | 3.0 |
*Fluorescent Dyes | 2 | 6.0 |
Heteroduplex Analysis | 2 | 2.0 |
*Organic Chemicals | 2 | 7.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
